RS20050777A - Postupak za lečenje ateroskleroze,dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije - Google Patents

Postupak za lečenje ateroskleroze,dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije

Info

Publication number
RS20050777A
RS20050777A YUP-2005/0777A YUP77705A RS20050777A RS 20050777 A RS20050777 A RS 20050777A YU P77705 A YUP77705 A YU P77705A RS 20050777 A RS20050777 A RS 20050777A
Authority
RS
Serbia
Prior art keywords
dyslipidemias
treating atherosclerosis
related conditions
pharmaceutical compo
compo sitions
Prior art date
Application number
YUP-2005/0777A
Other languages
English (en)
Inventor
Kang Cheng
Gerard Waters
Kathleen Metters
Gary O'Neill
Original Assignee
Merck & Co. Inc.,
Merck Frosst Canada Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20050777(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co. Inc.,, Merck Frosst Canada Ltd., filed Critical Merck & Co. Inc.,
Publication of RS20050777A publication Critical patent/RS20050777A/sr
Publication of RS52731B publication Critical patent/RS52731B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Dat je postupak za lečenje ateroskleroze koji obuhvata primenu na pacijenta nikotinske kiseline ili drugog agonista receptora za nikotinsku kiselinu u kombinaciji sa antagonistom DP receptora. Antagonist DP receptora primenjuje se radi smanjenja, prevencije ili eliminacije nastupa crvenila koje se inače može javiti.
YU20050777A 2003-05-15 2004-05-13 Farmaceutska kompozicija za upotrebu u lečenju ateroskleroze, dislipidemija i sa njima povezanih stanja RS52731B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15
PCT/US2004/014980 WO2004103370A1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
RS20050777A true RS20050777A (sr) 2008-04-04
RS52731B RS52731B (sr) 2013-08-30

Family

ID=33476734

Family Applications (3)

Application Number Title Priority Date Filing Date
RS20120498A RS20120498A1 (sr) 2003-05-15 2004-05-13 Postupak za lečenje ateroskleroze, dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije
RS20120499A RS20120499A1 (sr) 2003-05-15 2004-05-13 Postupak za lečenje ateroskleroze, dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije
YU20050777A RS52731B (sr) 2003-05-15 2004-05-13 Farmaceutska kompozicija za upotrebu u lečenju ateroskleroze, dislipidemija i sa njima povezanih stanja

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RS20120498A RS20120498A1 (sr) 2003-05-15 2004-05-13 Postupak za lečenje ateroskleroze, dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije
RS20120499A RS20120499A1 (sr) 2003-05-15 2004-05-13 Postupak za lečenje ateroskleroze, dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije

Country Status (45)

Country Link
US (4) US20040229844A1 (sr)
EP (3) EP2286816A1 (sr)
JP (2) JP4637833B2 (sr)
KR (2) KR100960749B1 (sr)
CN (3) CN102526735A (sr)
AR (1) AR041089A1 (sr)
AU (2) AU2004240597B2 (sr)
BR (1) BRPI0410273A (sr)
CA (1) CA2525772C (sr)
CL (1) CL2004001056A1 (sr)
CO (1) CO5630034A2 (sr)
CR (2) CR8047A (sr)
CY (2) CY1109476T1 (sr)
DE (1) DE602004022036D1 (sr)
DK (2) DK2116244T3 (sr)
DO (1) DOP2004000907A (sr)
EA (2) EA009744B1 (sr)
EC (1) ECSP056156A (sr)
ES (2) ES2328148T3 (sr)
GE (2) GEP20084569B (sr)
GT (1) GT200400098A (sr)
HK (1) HK1092722A1 (sr)
HN (1) HN2004000171A (sr)
HR (2) HRP20090424T1 (sr)
IL (1) IL171962A (sr)
IS (1) IS2708B (sr)
JO (1) JO2564B1 (sr)
MA (1) MA27835A1 (sr)
ME (1) MEP60108A (sr)
MX (1) MXPA05012272A (sr)
MY (1) MY140639A (sr)
NO (1) NO20055957L (sr)
NZ (2) NZ572515A (sr)
PA (1) PA8603201A1 (sr)
PE (1) PE20050552A1 (sr)
PL (2) PL1624871T3 (sr)
PT (2) PT1624871E (sr)
RS (3) RS20120498A1 (sr)
SG (1) SG153667A1 (sr)
SI (2) SI1624871T1 (sr)
TN (1) TNSN05290A1 (sr)
TW (2) TWI334354B (sr)
UA (1) UA89615C2 (sr)
WO (1) WO2004103370A1 (sr)
ZA (1) ZA200508288B (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
DE202005022112U1 (de) 2004-10-08 2014-04-24 Forward Pharma A/S Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
JP2008530250A (ja) * 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
JP2008538277A (ja) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 脂質関連障害の治療用の組成物および方法
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006247695B2 (en) * 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007027532A2 (en) * 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CN101305010A (zh) * 2005-09-01 2008-11-12 阿雷生物药品公司 Raf抑制剂化合物及其用法
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007075702A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
JP2009525961A (ja) * 2006-01-20 2009-07-16 シェーリング コーポレイション 異常脂質血症の処置のためのニコチン酸受容体アゴニストとしての複素環
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
MX2009002924A (es) 2006-09-15 2009-05-28 Schering Corp Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
EP2091534A1 (en) * 2006-09-15 2009-08-26 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
CN102083466A (zh) * 2008-05-20 2011-06-01 科莱尼斯医疗公司 用于组合疗法的烟酸和nsaid
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2341773A4 (en) * 2008-09-24 2012-03-07 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
KR101699912B1 (ko) 2009-01-09 2017-01-25 포워드 파마 에이/에스 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
BR112012023039A2 (pt) 2010-03-16 2016-05-17 Aventis Pharma Inc pirimidina substituída como um antagonista de receptor prostaglandina d2
CN103038228A (zh) 2010-03-16 2013-04-10 安万特药物公司 作为前列腺素d2受体拮抗剂的取代的嘧啶类化合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
JPS6352514B2 (sr) 1977-09-30 1988-10-19 Rca Corp
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2218696A1 (en) * 1995-04-19 1996-10-24 L. Jackson Ii Roberts Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs
WO1997016455A1 (en) 1995-10-31 1997-05-09 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
ATE228354T1 (de) 1995-12-22 2002-12-15 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
BR9815548A (pt) * 1997-07-31 2000-11-07 Kos Pharma Inc Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição
HUP0101110A3 (en) * 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
WO2000034240A1 (en) 1998-12-07 2000-06-15 Schering Corporation Process for the synthesis of azetidinones
EA200100704A1 (ru) 1998-12-23 2002-02-28 Джи.Ди.Сирл Ллс Комбинация для применения по сердечно-сосудистым показаниям
EP2281899A3 (en) 1999-04-05 2012-01-04 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-3(S)-hydroxy-3-(4-fluorophenyl)propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
WO2003022814A1 (fr) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives d'indole
CN1179945C (zh) 2000-03-09 2004-12-15 小野药品工业株式会社 吲哚衍生物、其制备方法及用途
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
KR20040095302A (ko) * 2002-03-19 2004-11-12 오노 야꾸힝 고교 가부시키가이샤 카르복실산 화합물 및 그 화합물을 유효 성분으로서함유하는 약제
RU2362555C2 (ru) * 2002-06-03 2009-07-27 Новартис Аг Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
CA2525772A1 (en) 2004-12-02
CA2525772C (en) 2011-03-15
CO5630034A2 (es) 2006-04-28
IL171962A (en) 2012-06-28
HRP20090424T1 (en) 2009-09-30
CN1787819A (zh) 2006-06-14
HRP20120818T1 (hr) 2012-11-30
GEP20084569B (en) 2008-12-25
GT200400098A (es) 2005-03-03
SI2116244T1 (sl) 2012-12-31
EP1624871B1 (en) 2009-07-15
DK2116244T3 (da) 2012-11-26
EA009744B1 (ru) 2008-04-28
JO2564B1 (en) 2010-11-03
MXPA05012272A (es) 2006-05-19
RS52731B (sr) 2013-08-30
MY140639A (en) 2010-01-15
IL171962A0 (en) 2006-04-10
KR100806008B1 (ko) 2008-02-26
TWI341199B (en) 2011-05-01
JP2010077151A (ja) 2010-04-08
CN102526735A (zh) 2012-07-04
JP2006526030A (ja) 2006-11-16
ECSP056156A (es) 2006-04-19
EA200702674A1 (ru) 2008-04-28
US20100076002A1 (en) 2010-03-25
PL1624871T3 (pl) 2009-12-31
KR20080003470A (ko) 2008-01-07
UA89615C2 (ru) 2010-02-25
TWI334354B (en) 2010-12-11
MEP60108A (en) 2011-05-10
DK1624871T3 (da) 2009-11-16
PT1624871E (pt) 2009-09-07
IS8071A (is) 2005-10-13
CY1109476T1 (el) 2014-08-13
PE20050552A1 (es) 2005-08-06
NZ543399A (en) 2009-02-28
GEP20105025B (en) 2010-06-25
AU2004240597A1 (en) 2004-12-02
RS20120498A1 (sr) 2013-08-30
EP2116244B1 (en) 2012-08-08
CN100441184C (zh) 2008-12-10
PA8603201A1 (es) 2005-02-04
EP2116244A1 (en) 2009-11-11
KR100960749B1 (ko) 2010-06-01
SG153667A1 (en) 2009-07-29
BRPI0410273A (pt) 2006-05-16
AU2011200986B2 (en) 2012-11-08
SI1624871T1 (sl) 2009-12-31
NZ572515A (en) 2010-07-30
EP1624871A1 (en) 2006-02-15
US20090233977A1 (en) 2009-09-17
CY1113342T1 (el) 2016-06-22
IS2708B (is) 2011-01-15
DOP2004000907A (es) 2004-11-30
PT2116244E (pt) 2012-11-02
CR9808A (es) 2008-07-29
EA011895B1 (ru) 2009-06-30
CN101559227B (zh) 2012-03-21
TNSN05290A1 (en) 2007-07-10
TW200803844A (en) 2008-01-16
US20110118292A1 (en) 2011-05-19
WO2004103370A1 (en) 2004-12-02
ZA200508288B (en) 2008-08-27
AU2004240597B2 (en) 2011-01-06
CN101559227A (zh) 2009-10-21
KR20060012617A (ko) 2006-02-08
EA200501817A1 (ru) 2006-06-30
TW200503757A (en) 2005-02-01
EP2286816A1 (en) 2011-02-23
MA27835A1 (fr) 2006-04-03
HK1092722A1 (en) 2007-02-16
US20040229844A1 (en) 2004-11-18
RS20120499A1 (sr) 2013-08-30
DE602004022036D1 (de) 2009-08-27
AU2011200986A1 (en) 2011-03-31
ES2328148T3 (es) 2009-11-10
JP4637833B2 (ja) 2011-02-23
CL2004001056A1 (es) 2005-03-28
HN2004000171A (es) 2011-07-11
CR8047A (es) 2006-07-14
PL2116244T3 (pl) 2013-01-31
NO20055957L (no) 2006-02-14
AR041089A1 (es) 2005-05-04
ES2392743T3 (es) 2012-12-13

Similar Documents

Publication Publication Date Title
RS20050777A (sr) Postupak za lečenje ateroskleroze,dislipidemija i sa njima povezanih stanja i farmaceutske kompozicije
WO2006089309A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
WO2006052798A3 (en) Method of treating pathological blushing
TW200607799A (en) Therapeutic compounds: pyridine as scaffold
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
WO2003099289A3 (en) Compositions and their uses for alleviating pain
WO2005072308A3 (en) Cgrp receptor antagonists
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2004071423A3 (en) Methods of administering opioid antagonists and compositions thereof
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2008097535A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP1387685A4 (en) ANALGETIC COMPOSITION AND METHOD
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2006026273A3 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
EA200802159A1 (ru) Введение агониста-антагониста пациентам с опиоидной зависимостью
MXPA03010407A (es) Prevencion de adiccion en gestion del dolor.
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
WO2005027853A3 (en) Method for treating snoring and sleep apnea with leukotriene antagonists